Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The biopharma industry is facing challenges with the rocky launch of Roctavian by Biomarin, as well as the departure of AbbVie CEO Richard Gonzalez. Frontier is making strides in developing a better KRAS drug with support from Galapagos. J&J has received EMA backing for earlier CAR-T use in multiple myeloma, and a NEJM paper explores a remarkable CAR-T result in autoimmune disease. Biosimilars are gaining traction in 2024 despite initial hurdles, reflecting an increase in market presence.Sanofi and Regeneron's Dupixent are undergoing a speedy FDA review for potential use in COPD, with a decision expected by June 27, 2024. AbbVie's success with Humira serves as a model for navigating the patent cliff, under the leadership of Richard Gonzalez. Frontier Medicines secures $80 million in Series C financing, while Blueprint's cancer drug Gavreto finds a new home at Rigel Pharmaceuticals. Bristol Myers Squibb is focusing on diverse therapeutic options for cancer treatment, leveraging advanced modalities. GSK ends its collaboration with Vir Biotechnology on anti-influenza antibodies, and Indian drugmakers explore the weight-loss market with new products. Yearlybird Health launches a $186 million venture capital fund.Despite recent staff cuts at companies like Galapagos, Adaptive, and Ring, the industry continues to offer job opportunities at companies like Amgen, Novo Nordisk, Kerecis, Life Edit, Emergent Biosolutions, and Moderna. Stay tuned for more updates on the latest developments in the biopharma industry.